Investigational drug · Phase 2
Quavonlimab
Also called: MK-1308
Not approved by FDA. In 2 industry-sponsored Phase 2 or 3 trials that are active or finished in the last two years, most often for Melanoma, Advanced Non-Small Cell Lung Cancer.
Phase 2Last checked: Nov 19, 2026Latest source record: Sep 1, 2026 (newest trial update)Source: ClinicalTrials.govMethods & limitations
Highest phase
Phase 2
Industry-sponsored trials
Phase 2 and 3 trials
2
0 still active
All registered trials
12
Any phase or sponsor naming "Quavonlimab"
First trial start
2018
Oct 1, 2018
Sponsors
Lead sponsors of its Phase 2 and 3 trials.
All registered trials by phase
Every ClinicalTrials.gov drug study naming "Quavonlimab", any sponsor or status.
- Phase 210
Conditions studied
As listed on its trial records.
- Melanoma
- Advanced Non-Small Cell Lung Cancer
Approved drugs for the same conditions: Non-small cell lung cancer · Small cell lung cancer · Melanoma · Oncology
Largest trials
Live from ClinicalTrials.gov: studies naming "Quavonlimab" as an intervention, largest first.
- A Study of Pembrolizumab (MK-3475) in Combination With Belzutifan (MK-6482) and Lenvatinib (MK-7902), or Pembrolizumab/Quavonlimab (MK-1308A) in Combination With Lenvatinib, Versus Pembrolizumab and Lenvatinib, for Treatment of Advanced Clear Cell Renal Cell Carcinoma (MK-6482-012)Pivotal-lookingActive, not recruiting
Merck Sharp & Dohme LLCMerck & Co. (MRK)
NCT04736706 · 1,688 participants · Start Apr 14, 2021 · Primary completion Feb 4, 2026
Drug: Pembrolizumab; Belzutifan and 2 more · For: Carcinoma, Renal Cell
Sites: Birmingham, Alabama; La Jolla, California; Los Angeles, California · 262 sites in all
Merck Sharp & Dohme LLCMerck & Co. (MRK)
NCT03179436 · 415 participants · Start Jul 2, 2017 · Primary completion Apr 8, 2024
Drug: Quavonlimab; Pembrolizumab and 1 more · For: Advanced Solid Tumors
Sites: Gilbert, Arizona; Hackensack, New Jersey; Nashville, Tennessee · 53 sites in all
- Substudy 03A: A Study of Immune and Targeted Combination Therapies in Participants With First Line (1L) Renal Cell Carcinoma (MK-3475-03A)Pivotal-lookingCompleted
Merck Sharp & Dohme LLCMerck & Co. (MRK)
NCT04626479 · 393 participants · Start Dec 16, 2020 · Primary completion Aug 10, 2026
Drug: Pembrolizumab; Favezelimab/Pembrolizumab and 4 more · For: Carcinoma, Renal Cell
Sites: San Francisco, California; New Haven, Connecticut; Chicago, Illinois · 55 sites in all
- Substudy 02B: Safety and Efficacy of Pembrolizumab in Combination With Investigational Agents or Pembrolizumab Alone in Participants With First Line (1L) Advanced Melanoma (MK-3475-02B/KEYMAKER-U02)Pivotal-lookingCompleted
Merck Sharp & Dohme LLCMerck & Co. (MRK)
NCT04305054 · 335 participants · Start Jul 1, 2020 · Primary completion May 18, 2026
Drug: Pembrolizumab; Vibostolimab and 4 more · For: Melanoma
Sites: Los Angeles, California; Santa Monica, California; Aurora, Colorado · 60 sites in all
Merck Sharp & Dohme LLCMerck & Co. (MRK)
NCT04895722 · 302 participants · Start Jun 25, 2021 · Primary completion May 21, 2025
Drug: Pembrolizumab; Pembrolizumab/Quavonlimab and 3 more · For: Colorectal Cancer
Sites: Orange City, Florida; Athens, Georgia; Chicago, Illinois · 109 sites in all
- Substudy 03B: A Study of Immune and Targeted Combination Therapies in Participants With Second Line Plus (2L+) Renal Cell Carcinoma (MK-3475-03B/KEYMAKER-U03)Pivotal-lookingCompleted
Merck Sharp & Dohme LLCMerck & Co. (MRK)
NCT04626518 · 263 participants · Start Dec 17, 2020 · Primary completion Jul 23, 2026
Drug: Pembrolizumab; MK-4830 and 4 more · For: Carcinoma, Renal Cell
Sites: San Francisco, California; New Haven, Connecticut; Chicago, Illinois · 51 sites in all
- A Study of Pembrolizumab (MK-3475) in Combination With Belzutifan (MK-6482) and Lenvatinib (MK-7902), or Pembrolizumab/Quavonlimab (MK-1308A) in Combination With Lenvatinib, vs Pembrolizumab and Lenvatinib, for Treatment of Advanced Clear Cell Renal Cell Carcinoma (MK-6482-012)-China Extension StudyPivotal-lookingActive, not recruiting
Merck Sharp & Dohme LLCMerck & Co. (MRK)
NCT05899049 · 251 participants · Start Jul 27, 2022 · Primary completion Feb 4, 2026
Drug: Pembrolizumab; Belzutifan and 2 more · For: Carcinoma, Renal Cell
Sites: Beijing, China; Chongqing, China; Guangzhou, China · 17 sites in all
- A Study of Biomarker-Directed, Pembrolizumab (MK-3475) Based Combination Therapy for Advanced Non-Small Cell Lung Cancer (MK-3475-495/KEYNOTE-495)Pivotal-lookingCompleted
Merck Sharp & Dohme LLCMerck & Co. (MRK)
NCT03516981 · 245 participants · Start Oct 1, 2018 · Primary completion Jun 13, 2025
Drug: Pembrolizumab; Favezelimab and 2 more · For: Advanced Non-Small Cell Lung Cancer
Sites: Tempe, Arizona; Sacramento, California; San Francisco, California · 81 sites in all
Merck Sharp & Dohme LLCMerck & Co. (MRK)
NCT04740307 · 116 participants · Start Mar 16, 2021 · Primary completion Jul 29, 2025
Drug: Pembrolizumab/Quavonlimab; Lenvatinib and 1 more · For: Advanced Hepatocellular Carcinoma
Sites: Duarte, California; Baltimore, Maryland; New York, New York · 40 sites in all
- Safety and Efficacy Study of Investigational Agents as Monotherapy or in Combination With Pembrolizumab (MK-3475) for the Treatment of Extensive-Stage Small Cell Lung Cancer (ES-SCLC) in Need of Second-Line Therapy (MK-3475-B98/KEYNOTE-B98)Pivotal-lookingActive, not recruiting
Merck Sharp & Dohme LLCMerck & Co. (MRK)
NCT04938817 · 110 participants (planned) · Start Aug 19, 2021 · Primary completion Dec 10, 2029
Drug: coformulation pembrolizumab/quavonlimab; lenvatinib and 3 more · For: Small Cell Lung Carcinoma
Sites: Gilbert, Arizona; Atlanta, Georgia; Fort Wayne, Indiana · 48 sites in all
Newest research
PubMed records naming it or its code names, newest first.
No PubMed records name it yet, which is common for early code-named drugs.
Also in development for Melanoma
- RilvegostomigAZD2936Phase 325 trials
AstraZeneca · Biliary Tract Cancer, Gastric Cancer, Non-small Cell Lung Cancer
- FianlimabREGN3767Phase 311 trials
Regeneron · Melanoma, Non-small Cell Lung Cancer, Hepatocellular Carcinoma
- IfebemtinibIN10018, BI853520Phase 311 trials
InxMed (Shanghai) Co., Ltd. · Solid Tumor, NSCLC, Solid Tumor Cancer
- Intismeran autogeneV940, mRNA-4157Phase 310 trials
Merck & Co. · Non-small Cell Lung Cancer, Melanoma, Bladder Cancer
- FavezelimabMK-4280, MK-4820APhase 39 trials
Merck & Co. · Melanoma, Carcinoma, Renal Cell, Solid Tumors
- IBI363Phase 37 trials
Innovent Biologics (Suzhou) Co. Ltd. · Melanoma, Colorectal Cancer, Resectable Stage II-III Non-small Cell Lung Cancer
- OH2Phase 36 trials
Binhui Biopharmaceutical Co., Ltd. · Melanoma, Solid Tumor, Gastrointestinal Cancer
- PucotenlimabHX008Phase 36 trials
Lepu Biopharma Co., Ltd. · Head and Neck Squamous Cell Carcinoma, Melanoma, Hepatocellular Carcinoma
Names are merged from how sponsors list this drug on ClinicalTrials.gov, so an alias can occasionally belong to a related compound. Development status changes faster than registry records do. More from Merck & Co..
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.